An under-$10 stock in the biotechnology and drugs complex that's setting up to trigger a major breakout trade is Rosetta Genomics (ROSG), which develops and commercializes diagnostic tests based on microRNAs. This stock has been on fire so far in 2012, with shares up a whopping 170%.
If you take a look at the chart for Rosetta Genomics, you'll see that this stock recently spiked back above both its 50-day and 200-day moving averages with above-average volume. This move has also pushed ROSG back above some near-term overhead resistance at $6.87 to $7.19 a share with decent volume. Now ROSG is flirting with some more overhead resistance at $7.56 a share, which is quickly pushing the stock into breakout territory.Market players should now look for long-biased trades in ROSG as long as it's trending above those overhead resistance levels at $7.19 to $7.56 a share with strong upside volume flows. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 1.7 million shares. If ROSG can maintain that trend, then this stock has a great chance of trending higher back towards its next significant overhead resistance levels at $11.47 to $12.87 a share. Traders can now look to buy ROSG off any weakness and simply use a stop that sits just below some near-term support at $6.90 a share. One could also buy ROSG off strength as long as it's rending above $7.19 with strong upside volume flows. Keep in mind that ROSG has hit an intraday high today of $7.73 a share, so that is another reference point that breakout traders should watch.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV